Pravastatin cholesterol lowering intervention

Lipostat - Pravasin - Pravacol - Selektine - Elisor - Pravachol - Mevalotin - Prareduct - Lipemol - CS514 - CS 514 - CS-514 - Bristacol - Vasten - SQ31000 - SQ 31000 - SQ-31000 - RMS431 - RMS 431 - RMS-431 - Liplat - Eptastatin - Pravastatin

Acute coronary syndrome

Early initiation:  6 trials  - LAMIL - RECIFE - L-CAD - PAIS - PTT - PACT

pravastatin vs placebo

No demonstrated result

suggested Non fatal MI by 82% (not demonstrated)

pravastatin vs usual care

No demonstrated result

Atrial fibrillation

Patient with history of atrial fibrillation:  1 trials  - Tveit

pravastatin vs control

No demonstrated result

Cardiovascular prevention

All chronical situations:  14 trials  - PROSPER - ALLHAT - PLAC I - PLAC II - PACT - KAPS - LIPID - CARE - WOSCOPS - MEGA - REGRESS - PMSG - CAIUS - GISSI Prevenzione

pravastatin vs control

No demonstrated result

suggested cardiovascular events by 25% (not demonstrated)

suggested Coronary event by 33% (not demonstrated)

suggested Coronary death by 47% (not demonstrated)

suggested MACE by 30% (not demonstrated)

pravastatin vs placebo

cardiovascular events by 24% (fully demonstrated)

Coronary event by 23% (fully demonstrated)

Coronary death by 22% (fully demonstrated)

suggested Cardiovascular death by 22% (not demonstrated)

suggested stroke (fatal and non fatal) by 13% (not demonstrated)

suggested Coronary death and non fatal MI by 23% (not demonstrated)

suggested cardiac death by 24% (not demonstrated)

suggested MACE by 18% (not demonstrated)

suggested Non fatal MI by 19% (not demonstrated)

suggested All cause death by 16% (not demonstrated)

pravastatin vs usual care

No demonstrated result
See more clinical conditions

Diabetic patients :  7 trials  - PROSPER diabetic (sub group) - LIPID (diabetic sub group) - CARE (diabetic sub group) - WOSCOPS (diabetic sub group) - GISSI P (diabetic sub group) - ALLHAT-LLT (diabetic sub group) - PROVE IT TIMI 22 (diabetic sub group)

pravastatin vs placebo

No demonstrated result
pravastatin vs usual care

No demonstrated result
pravastatin high dose vs pravastatin

No demonstrated result

Elderly:  5 trials  - PROSPER - CARE (elderly subgroup) - LIPID (elderly sub group) - PLAC I (elderly sub group) - REGRESS (elderly subgroup)

pravastatin vs placebo

No demonstrated result

new-onset diabetes by 32% (harmful effect)

suggested Coronary death and non fatal MI by 17% (not demonstrated)

suggested Coronary event by 17% (not demonstrated)

suggested Coronary death by 26% (not demonstrated)

suggested Non fatal MI by 17% (not demonstrated)

suggested Revascularization by 28% (not demonstrated)

suggested All cause death by 14% (not demonstrated)

High risk patients with or without LDL cholesterol elevation:  4 trials  - PROSPER - ALLHAT - REGRESS - PMSG

pravastatin vs placebo

cardiovascular events by 17% (fully demonstrated)

new-onset diabetes by 32% (harmful effect)

suggested Coronary death and non fatal MI by 18% (not demonstrated)

suggested Coronary event by 18% (not demonstrated)

suggested MACE by 16% (not demonstrated)

pravastatin vs usual care

No demonstrated result

Hypertensive patients:  1 trials  - ALLHAT

pravastatin vs usual care

No demonstrated result

Patient with related disease:  1 trials  - PREVEND IT

pravastatin vs placebo

No demonstrated result

Patients with LDL elevation and without CHD:  1 trials  - WOSCOPS

pravastatin vs placebo

Coronary event by 30% (fully demonstrated)

suggested cardiovascular events by 42% (not demonstrated)

suggested Cardiovascular death by 32% (not demonstrated)

suggested Coronary death and non fatal MI by 30% (not demonstrated)

suggested Non fatal MI by 30% (not demonstrated)

Patients with other atherosclerotic localisation:  1 trials  - CAIUS

pravastatin vs placebo

No demonstrated result

Patients with prior MI or with CHD:  9 trials  - LIPID - CARE - LAMIL - RECIFE - L-CAD - PAIS - PTT - PACT - GISSI Prevenzione

pravastatin vs placebo

Coronary event by 22% (fully demonstrated)

Coronary death by 22% (fully demonstrated)

suggested Cardiovascular death by 24% (not demonstrated)

suggested stroke (fatal and non fatal) by 21% (not demonstrated)

suggested Coronary death and non fatal MI by 22% (not demonstrated)

suggested Non fatal MI by 31% (not demonstrated)

suggested All cause death by 19% (not demonstrated)

pravastatin vs usual care

No demonstrated result

Primary prevention:  10 trials  - ALLHAT - KAPS - WOSCOPS - MEGA - PMSG - CAIUS - FAST Fukuoka pravastatin - KLIS - PHYLLIS - PROSPER (primary prevention subgroup)

pravastatin vs control

No demonstrated result

suggested cardiovascular events by 25% (not demonstrated)

suggested Coronary event by 33% (not demonstrated)

suggested Coronary death by 47% (not demonstrated)

suggested MACE by 30% (not demonstrated)

pravastatin vs placebo

Coronary event by 23% (fully demonstrated)

suggested cardiovascular events by 40% (not demonstrated)

suggested Cardiovascular death by 32% (not demonstrated)

suggested Coronary death and non fatal MI by 30% (not demonstrated)

suggested Non fatal MI by 30% (not demonstrated)

pravastatin vs usual care

No demonstrated result

Secondary prevention:  8 trials  - PROSPER - PLAC I - PLAC II - PACT - LIPID - CARE - REGRESS - GISSI Prevenzione

pravastatin vs placebo

cardiovascular events by 17% (fully demonstrated)

Coronary event by 22% (fully demonstrated)

Coronary death by 21% (fully demonstrated)

suggested Cardiovascular death by 21% (not demonstrated)

suggested stroke (fatal and non fatal) by 13% (not demonstrated)

suggested Coronary death and non fatal MI by 22% (not demonstrated)

suggested MACE by 18% (not demonstrated)

suggested Non fatal MI by 14% (not demonstrated)

suggested All cause death by 15% (not demonstrated)

pravastatin vs usual care

No demonstrated result

Women:  2 trials  - ALLHAT (women subgroup) - MEGA (women subgroup)

Pravastatin vs placebo

No demonstrated result

suggested All cause death by 42% (not demonstrated)

Diabetes type 2

Diabetic patients with or withour hypercholesterolemia:  7 trials  - PROSPER diabetic (sub group) - LIPID (diabetic sub group) - CARE (diabetic sub group) - WOSCOPS (diabetic sub group) - GISSI P (diabetic sub group) - ALLHAT-LLT (diabetic sub group) - PROVE IT TIMI 22 (diabetic sub group)

pravastatin vs placebo

No demonstrated result
pravastatin vs usual care

No demonstrated result
pravastatin high dose vs pravastatin

No demonstrated result
See more clinical conditions

Primary prevention:  1 trials  - WOSCOPS (diabetic sub group)

pravastatin vs placebo

No demonstrated result

Secondary prevention:  5 trials  - PROSPER diabetic (sub group) - LIPID (diabetic sub group) - CARE (diabetic sub group) - GISSI P (diabetic sub group) - PROVE IT TIMI 22 (diabetic sub group)

pravastatin vs placebo

No demonstrated result
pravastatin vs usual care

No demonstrated result
pravastatin high dose vs pravastatin

No demonstrated result

Percutaneous coronary intervention

All type of patients:  1 trials  - PREDICT

pravastatin vs placebo

No demonstrated result

Peripheral vascular diseases

Post myocardial infarction

All type of patients:  3 trials  - PACT - LIPID - CARE

pravastatin vs placebo

Coronary event by 22% (fully demonstrated)

Coronary death by 21% (fully demonstrated)

suggested Cardiovascular death by 24% (not demonstrated)

suggested stroke (fatal and non fatal) by 21% (not demonstrated)

suggested Coronary death and non fatal MI by 22% (not demonstrated)

suggested All cause death by 19% (not demonstrated)




- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons